Products are for research use only, not for human use

Peptide

Snap-8 (acetyl octapeptide-3)

Snap-8 is a synthetic octapeptide, Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, copying residues 12 to 19 of the neuronal protein SNAP-25. Its N-terminus is acetylated and its C-terminus amidated.

Updated · 31 sources read · How this library is built

  1. E1
  2. E2
  3. M3
  4. Q4
  5. R5
  6. R6
  7. A7
  8. D8
One-letter code, Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2: acetyl on the N-terminal amine, amide on the alpha-carboxyl of Asp8 with the aspartate side chain left as a free acid, all eight residues L, no disulfide and no cyclisation. Outlined positions carry a modification listed below.

Snap-8 in brief

Snap-8 is the trade-style name for acetyl octapeptide-3, a synthetic octapeptide, Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, copying residues 12 to 19 of the neuronal SNARE protein SNAP-25 with both termini capped. It is the two-residue extension of an earlier hexapeptide, and its literature sits almost entirely inside cosmetic-ingredient reviews, formulation studies and one analytical method paper. The stated mechanism, competition with SNAP-25 during SNARE complex assembly, and the one circulating inhibition figure both trace to the originator's own technical material. No binding constant, peer-reviewed potency figure or three-dimensional structure exists, and public registry records give three different masses for the substance.[1,2,3,4,5,6]

Snap-8 regulatory status

The substance is a cosmetic ingredient rather than a medicine, and it holds no International Nonproprietary Name. The FDA substance registry records Acetyl Octapeptide-3 as its official name, which is the INCI name, SNAP-8 as a brand name, and Acetyl Glutamyl Heptapeptide-3 and Acetyl octapeptide 1 as common names, all against one unique ingredient identifier. No marketing authorisation was found in Drugs@FDA, the EMA medicines database or the Health Canada Drug Product Database (searched November 2026). The FDA states that cosmetic products and ingredients, with the exception of colour additives, do not need FDA premarket approval, so nothing here has been reviewed by a regulator for either safety or effect. It is named nowhere on the WADA 2026 Prohibited List. It appears neither in the FDA list of bulk drug substances that may present significant safety risks, which therefore records no agency concern against it, nor among the nominations that page lists as withdrawn (checked November 2026), and no retraction or expression of concern was found on any work cited here.[1,7,8,9,10,11,12]

Snap-8 at a glance

  • A cosmetic ingredient, not a medicine, and it holds no International Nonproprietary Name: the regulated name is the INCI name acetyl octapeptide-3, which is also the official name on the FDA substance record. No marketing authorisation was found in Drugs@FDA, the EMA medicines database or the Health Canada Drug Product Database; cosmetic ingredients other than colour additives need no FDA premarket approval; and the substance is named nowhere on the WADA 2026 Prohibited List.[1,7,8,9,10,11]
  • The sequence occurs once in human SNAP-25, at residues 12 to 19, inside the protein's N-terminal SNARE motif. The related hexapeptide covers residues 12 to 17 of the same stretch.[2,13]
  • Eight proteinogenic L residues, EEMQRRAD, acetyl on the N-terminal amine and a primary amide on the C-terminal alpha-carboxyl: C41H70N16O16S, average mass 1075.2. Public records carry three different masses for the one substance, and which record a reader opens decides which figure they take. The three are set out under What remains unresolved.[6,1,14]
  • One peer-reviewed paper in the literature read measures this molecule on its own, and it is an analytical method rather than a pharmacology experiment. No binding constant, no potency figure from a peer-reviewed assay and no deposited or computed three-dimensional structure were found, and no independent experiment supports the mechanism the ingredient is described by. The quantitative inhibition figure that circulates in reviews, 43 percent at an assay concentration of 1.5 millimolar, is attributed there to the originator's own product literature.[4,5,15]
  • The best-characterised measurement on the molecule is analytical: a validated LC-MS/MS method quantifies it through the doubly protonated ion at m/z 538, with the singly protonated ion at m/z 1076 too weak to use, and found it stable in water at 4 degrees Celsius for at least 96 hours.[4]

What is Snap-8?

Snap-8 is a short synthetic peptide built by copying a fragment of a protein. The protein is SNAP-25, one of three proteins whose coiled helices form the SNARE complex, the assembly that pulls a neurotransmitter-filled vesicle against the cell membrane so the two can fuse. The copied fragment is residues 12 to 19 of the human sequence, and the copy is capped at both ends, acetyl on the amine and amide on the carboxyl, which removes the two charges a free peptide terminus would carry.[2,1,16]

It is the two-residue extension of an earlier six-residue peptide, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, reported in 2002 as the product of a design programme that set out to interfere with SNARE complex assembly without the protease activity of the bacterial neurotoxin that cuts SNAP-25. The published description of the octapeptide, consistent across the reviews that list it, is that it competes with SNAP-25 for a place in the forming complex. That description comes to the secondary literature from the originator's technical material rather than from an independent experiment.[3,5,17]

Several names reach a label for this one substance, and the registry sorts them. The FDA substance record holds Acetyl Octapeptide-3 as the official name, which is the INCI name, SNAP-8 as a brand name, and both Acetyl Glutamyl Heptapeptide-3 and Acetyl octapeptide 1 as common names, all against the single identifier 8K14HJF88S. The heptapeptide spelling is not a different molecule: that name parses as an acetylated glutamate followed by a seven-residue chain, which is the same eight residues counted another way. No International Nonproprietary Name has been assigned to the substance, so there is no pharmaceutical name to set beside the cosmetic one.[1]

Beside the two ingredient names it is most often sold next to, the registry makes the differences plain. Acetyl hexapeptide-8 is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2: six residues, the same two caps, covering SNAP-25 residues 12 to 17, and its FDA record carries Argireline as a common name and acetyl hexapeptide-3 as the older spelling of the same substance, which is why the two hexapeptide names on labels are one ingredient. This octapeptide is that chain with Ala-Asp added: eight residues, SNAP-25 residues 12 to 19, one further free carboxylate. Pentapeptide-18 is not a member of the family at all. The registry gives it as Tyr-D-Ala-Gly-Phe-Leu, C29H39N5O7 at 569.65, a leucine-enkephalin analogue carrying a D-residue, with no acetyl cap, no C-terminal amide and no SNAP-25 sequence in it. The measured chemistry is distributed far less evenly than the structures are similar: the cytotoxicity screen, the skin-penetration work and the detection of methionine oxidation in marketed products were all done on the hexapeptide, one analytical method paper is the only peer-reviewed measurement on this octapeptide, and the pentapeptide appears here only as the other name in the same product tables.[18,19,2,20,21,22,4,5]

Its literature has an unusual shape. PubMed indexes no paper whose title or abstract names the compound at all: every mention reached by searching sits inside a full text, a sequence table or a formulation list. The molecule appears as one ingredient among several in patch studies, in an analytical method paper, in one computational docking study and in a run of narrative reviews that cite each other and the manufacturer. A 2026 appraisal of this class states that skin-surface efficacy measurements on the parent hexapeptide do not prove interruption of signalling at the neuromuscular target, and that this octapeptide and pentapeptide-18 are related commercial concepts rather than interchangeable substitutes for it, the evidence not justifying an equivalent mechanism across the group. That shape carries into the cards below: one of them measures this molecule on its own, and the rest concern the parent hexapeptide, other peptide families, formulated patches carrying three or five actives at once, or a computational model, each saying so in its own limitation.[4,23,24,25,15]

So the written chemistry is settled, and it is a defined single substance rather than a mixture, while nothing about a molecular target is. The registry records do not even agree on the structure diagram, which is unusual for a compound of this age and commercial reach.[1,6,14]

Not to be confused with

Acetyl hexapeptide-3 or -8, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2
The six-residue peptide this one extends, covering SNAP-25 residues 12 to 17 (CID 71587772, C35H62N14O11S, 887.0). The octapeptide adds Ala-Asp, two further residues and one more carboxylate. The hexapeptide depiction in that registry record carries the same enamine artefact as the cross-referenced octapeptide record, so its listed formula and mass are not a clean comparator either. Almost all of the measured chemistry, cell work and skin-penetration work in this family was done on the hexapeptide, and a finding for one is not a finding for the other.[13,2,15]
SNAP-25 itself
A 206-residue membrane-associated protein and one of the three components of the neuronal SNARE complex. Residues 12 to 19 sit inside the protein's N-terminal SNARE motif, so the octapeptide reproduces eight residues of that motif and none of the remainder of it, none of the C-terminal SNARE motif, and neither the linker nor the palmitoylated cysteine cluster.[2,16]
The SNAP-25-derived blocking peptides of the 1990s
A 20-mer patterned on the SNAP-25 C-terminus and the 26-mer released when botulinum neurotoxin E cleaves SNAP-25. Both are long C-terminal fragments with measured effects on vesicle docking, and both are frequently cited in secondary descriptions of this octapeptide, which is short and N-terminal.[34,31]
Botulinum neurotoxin type A
A bacterial protease that cuts SNAP-25. This is a short unmodified peptide with no catalytic activity, no targeting domain and no demonstrated cell entry. The 2026 appraisal of this class states that the parent hexapeptide should not be treated as pharmacologically equivalent to the bacterial neurotoxin, and names this octapeptide as a related commercial concept rather than an interchangeable one.[15,31]
Snapin and VAMP2-derived exocytosis-blocking peptides
Separate designed peptides aimed at the same machinery, most of them lipidated or fused to a cell-penetrating sequence precisely so that they can reach the cytosol. They are the comparison cases, not other names for this molecule.[29,35,28]

Snap-8 structure and sequence

The chain reads Glu1-Glu2-Met3-Gln4-Arg5-Arg6-Ala7-Asp8. Three of the eight side chains are acidic (two glutamates and the aspartate) and two are the strongly basic guanidinium groups of arginine, so around neutral pH the molecule carries several charges of each sign and a net charge close to zero while remaining very hydrophilic: PubChem computes 17 hydrogen-bond donors, 19 acceptors and an XLogP of -7.7 across 74 heavy atoms. There is no aromatic residue, so the peptide has no useful absorbance near 280 nanometres, which is part of why its quantification was developed by mass spectrometry rather than by ultraviolet detection.[6,4]

The single methionine at position 3 is the molecule's chemically reactive point. In the hexapeptide analogue, which shares that residue, reversed-phase liquid chromatography with tandem mass spectrometry detected both the peptide and its methionine-oxidised form in marketed products, and neutral-loss experiments assigned the oxidation to that residue; the authors built a sample-preparation step specifically to limit and monitor it. The same liability follows from the same chemistry here, and nothing has been published that measures it for this peptide.[20,6]

There is nothing three-dimensional to show, by either route: no experimental structure of the capped octapeptide has been deposited, and PubChem's 3D endpoint answers 404 for both of its depictions. The nearest thing in the archive is the protein the sequence was taken from. In the 2.4 angstrom crystal structure of the neuronal synaptic fusion complex the N-terminal SNAP-25B chain is observed from residue 7 onwards, with a single helix annotated from residue 8 to residue 81, so this peptide's parent segment is helical there, inside a twisted parallel four-helix bundle with leucine-zipper-like layers and a central ionic layer of one arginine and three glutamines. That is the protein in an assembled complex, not evidence that eight residues cut out of it and capped adopt the same helix alone, and work on the same protein's N-terminus found inhibitory potency tracking a peptide's propensity to form an alpha-helix.[6,14,26,16,27]

Modifications

  • Glu1 alpha-amine N-terminal acetylation. The FDA substance record codes it as an acetyl glutamic acid residue at the N-terminus, and the PubChem depiction of the capped molecule draws the same acetamide.[1,6]
  • Asp8 alpha-carboxyl C-terminal primary amide. The substance record expresses this as a substitution to isoasparagine, which is how it denotes an amide on the alpha-carboxyl of an aspartate whose side-chain carboxyl stays free; the PubChem SMILES for CID 76283482 draws exactly that arrangement.[1,6]

Eight stereocentres, one per residue and all S, which is what PubChem's atom-stereocentre count and the (3S,6S,9S,12S,15S,18S,21S,24S) locants of the systematic name both record; the eight residues are the ordinary L forms and no D residue or non-proteinogenic residue appears in any record. There is no disulfide, no cyclisation, no lipid and no glycan, so the molecule is a short linear chain with 38 rotatable bonds by PubChem's count. Its charge is strongly pH-dependent: two glutamate side chains and one aspartate against two arginines, so the net charge is near zero around neutral pH while the molecule stays highly polar, with a computed XLogP of -7.7.[6]

What studies on Snap-8 show

Each card names the experimental system and what was measured. A result in one system is not evidence about another.

The only peer-reviewed measurement on this molecule: validated LC-MS/MS quantification · Triple quadrupole mass spectrometer, positive electrospray, multiple reaction monitoring; blank and loaded biodegradable microneedle patch matrix

The doubly protonated ion at m/z 538 was the only workable precursor: the singly protonated ion at m/z 1076 was weak and the triply protonated ion was not detected. Three product ions at m/z 102, 84 and 144 were optimised, linearity gave r = 0.9971, the quantification limit was 0.0125 nanograms per milligram of patch, relative standard deviation ran 0.02 to 0.12 percent and relative error -1.68 to 1.44 percent. Filtration recovery was 76.7 percent, matrix calibration read 16.3 percent lower than water calibration, and the peptide was unchanged in water at 4 degrees Celsius through 96 hours.[4]

Material
Acetyl octapeptide-3 obtained from the originating manufacturer, with acetyl hexapeptide-3 as internal standard
Measured
Charge-state distribution, product ions and collision energies, linearity, detection and quantification limits, recovery, matrix effect, and stability in water at 4 degrees Celsius
Compared with
Acetyl hexapeptide-3 internal standard; water-based against matrix-based calibration
Limitation
An analytical validation, not a pharmacology experiment: it establishes how to measure the molecule and that it survives refrigerated aqueous storage for four days, and says nothing about a target. The three product ions are small and shared with the hexapeptide, so the method's specificity rests on chromatographic separation rather than on a unique fragment.

Ji M et al., 2020, Journal of Analytical Science and Technology

Molecular docking and molecular dynamics simulation · In silico only, synaptotagmin 1 C2A and C2B domains

Every peptide in the panel was placed in a cleft at the C2A-C2B interface and the simulations reported increased rigidity of the protein, from which the authors inferred suppression of its closed-to-open transition.[23]

Material
A panel the abstract describes only as botox-like peptides; no member is named in the abstract and the full text is subscription-only, so this octapeptide's presence in the panel is unconfirmed
Measured
Docking pose and simulated protein flexibility
Compared with
The other peptides in the panel
Limitation
Entirely computational: a pose and a simulated rigidity change, with no binding measurement, no affinity, no cellular test and no experimental validation of the proposed site. It also nominates a different target, the calcium sensor synaptotagmin, from the SNARE-assembly mechanism the compound is described by elsewhere, and the two accounts have never been tested against each other. Read at abstract level, and the abstract names no member of the modelled panel, so whether this octapeptide was among them could not be verified from what was read.

Wongrattanakamon P et al., 2018, Molecular and Cellular Biochemistry

Split-face clinical study of a formulated patch · 24 healthy volunteers, left and right periocular sites, 28 days

Roughness parameters at the treated site changed relative to the placebo patch over the study period, and no adverse effects were recorded on repeated application to the same area.[24]

Material
Hyaluronic acid dissolving microneedle patch carrying the octapeptide alongside ascorbyl glucoside and a cyclic lysophosphatidic acid salt
Measured
Skin roughness parameters on two instrumental systems, transepidermal water loss, and adverse effects
Compared with
A hyaluronic-acid-only patch on the contralateral side
Limitation
Three actives plus a physical microneedle array in one patch, so the design cannot attribute any part of the change to this peptide; the authors' assignment of the early change to it is an inference. The paper also prints the ingredient's molecular weight as 105.16, an order of magnitude below the registry value, which is a transcription error on the one characterisation figure it gives.

Shin JY et al., 2024, Annals of Dermatology

Monocentric clinical study of a formulated patch · Healthy subjects with aged skin, periocular and forearm sites, 12 weeks

Instrumental changes were reported at the treated sites and no primary or cumulative skin reactions occurred.[25]

Material
Hyaluronic acid microneedle patch containing an arginine and lysine polypeptide, this octapeptide, palmitoyl tripeptide-5, adenosine and seaweed extracts
Measured
Instrumental line depth, hydration, dermal density and thickness, and dermal tolerability
Compared with
None described in the abstract
Limitation
Five actives in one patch with no placebo arm described, read at abstract level only, and the authors themselves attribute the outcome to the combination. It establishes that the ingredient is used in formulations and nothing about the ingredient.

Avcil M et al., 2020, Journal of Cosmetic Dermatology

In vitro SNARE assembly and exocytosis assays · Reconstituted SNARE complex; detergent-permeabilised excitable cells; intact hippocampal neurones

The segment spanning Ala22 to Ile44 of SNAP-25 was identified as essential for complex formation, peptides from that region inhibited assembly with a potency correlating with their propensity to form an alpha-helix, and they acted only when added before assembly began.[27]

Material
Synthetic peptides patterned after the N-terminal domain of SNAP-25
Measured
SNARE complex formation, disruption of the SNAP-25 and syntaxin binary complex, and evoked release
Compared with
Inactive sequence variants; botulinum neurotoxins as a potency reference
Limitation
The active region is residues 22 to 44, downstream of the 12 to 19 segment this entry is about, so the paper supports the mechanistic class and not this molecule. Read at abstract level. The helicity correlation and the before-assembly-only requirement are both awkward for a short capped octapeptide applied to intact skin.

Blanes-Mira C et al., 2004, Journal of Neurochemistry

Degranulation and SNARE complex formation assays with and without a delivery module · Mast cells, in vitro SNARE assembly, mouse models of atopic dermatitis

The VAMP-derived N-terminal peptides inhibited SNARE complex formation and reduced degranulation, and fusing a transduction domain to them was what allowed them to enter intact cells as effectively as chemically permeabilised ones.[28]

Material
N-terminal peptides of VAMP2 and VAMP8, alone and fused to protein transduction domains
Measured
SNARE complex formation and granule release
Compared with
Streptolysin-O permeabilisation as the alternative route into the cell
Limitation
A different peptide family. Its value here is the control it includes: in this class, reaching the cytosol of an intact cell required an added delivery sequence, which this octapeptide does not have. The paper's one sentence about this octapeptide is uncited background.

Yang Y et al., 2018, Frontiers in Immunology

In silico design followed by cellular and animal assays · Rat dorsal root ganglion neurones, human LAN-2 neuroblastoma cells, pilocarpine-stimulated mouse model

Designed peptides reduced calcium-dependent exocytosis and CGRP release in rat neurones, and the two most potent, both carrying a palmitoyl group, suppressed acetylcholine release in the human cell line.[29]

Material
Eleven designed peptides targeting Snapin-SNARE assembly, the leading candidates palmitoylated
Measured
Calcium-dependent vesicle exocytosis, alpha-CGRP release, acetylcholine release
Compared with
Inactive designs within the same panel
Limitation
Different peptides, and read at abstract level. It is included because it shows what a measured exocytosis experiment on this target looks like, and because the candidates that worked needed lipidation, which this peptide does not have.

Butron L et al., 2023, Experimental Dermatology

Snap-8 compared with GHK-Cu and KPV

Four things about the 2 compounds most often read beside it, on axes that can be checked: what kind of substance it is, its formula and mass, what public records settle about which substance it is, and the strongest three-dimensional evidence that exists for it. Every figure is the one stated on that compound's own page, which is where it is cited, so the two can never disagree. The table compares no effect, no potency and nothing a compound has been reported to do, and these compounds are not alternatives to one another.

CompoundKindFormula and massIdentity on the public recordStrongest structure evidence
Snap-8 (acetyl octapeptide-3)Peptide8 residues, C41H70N16O16S, 1075.2 g/molOne species, pinned by public recordsNo three-dimensional model
GHK-CuMetal complex3 residues, C14H22CuN6O4, 401.91 g/molOne species, pinned by public recordsNo three-dimensional model
KPVPeptide3 residues, C16H30N4O4, 342.43 g/molOne species, pinned by public recordsComputed database conformer

What is claimed about acetyl octapeptide-3 at the SNARE complex, and what has actually been measured

The published account is competition. SNAP-25 contributes two of the four helices of the SNARE complex, and the proposal is that a free peptide carrying part of the protein's N-terminal motif occupies a place in the forming bundle, so fewer complete complexes assemble and less neurotransmitter is released. Every statement of that account in the literature read traces back to the originator's technical material, through reviews that repeat it. So does every number: a review that tabulates this family quotes 43 percent inhibition of glutamate release at an assay concentration of 1.5 millimolar, and a combination figure of 47 percent for this octapeptide with a pentapeptide at 0.75 millimolar each against 38 and 7 percent for each alone, and attributes all of them to the manufacturer's own website and dossier rather than to a peer-reviewed experiment. No assay, cell type, replicate count or error estimate is given with them, a millimolar working concentration is very high for something described as a competitive inhibitor, and none of it can be independently checked. Those are the only quantitative figures for the compound in the literature read.[5,17,16,15]

Three things in the independent literature sit awkwardly with it, and none of them refutes it. The segment mapped as essential for complex formation, and the one from which inhibitory peptides were actually obtained, is residues 22 to 44 rather than 12 to 19, and there potency tracked a peptide's propensity to form an alpha-helix. The peptides that did inhibit anywhere in this literature are substantially longer than eight residues: a 26-mer released by neurotoxin cleavage of the protein, and, from a helix-constrained combinatorial search, a 17-mer unrelated to any SNARE protein. And the target is intracellular: related peptides reached it only after chemical permeabilisation, a fused cell-penetrating sequence or a palmitoyl group, while this is a small, very hydrophilic, multiply charged peptide with no delivery element.[27,30,31,28,29,6]

A second, incompatible mechanism has also been proposed for the same molecule. A molecular-modelling study placed a panel of marketed cosmetic peptides, described in its abstract only as botox-like peptides, in a cleft between the two C2 domains of synaptotagmin 1, the calcium sensor of the release machinery, and inferred that the binding would hold the protein rigid. That is a docking result and a simulation, with no binding measurement behind it, and because the abstract names no member of the panel and the full text is subscription-only, this octapeptide's presence in it is unconfirmed. So there are two accounts of how this peptide might act, one from a manufacturer dossier and one from a computational model, and no experiment in the public literature that distinguishes them or establishes either.[23,5]

An abstract illustration standing for the kind of process this entry describes. It depicts no molecule and carries no text.
An abstract illustration, chosen to suit the kind of process this page describes. It is decoration rather than evidence: nothing in it is specific to this compound, nothing in it was measured, and it depicts no molecule. Generated from this entry's topic list. Volta Peptides compound library. CC0 1.0

What is still unknown about Snap-8

Identity is resolved; the records that state it are not internally consistent. The amide position is pinned down twice over: the FDA record codes the C-terminal residue as isoasparagine, meaning the amide is on the alpha-carboxyl with the aspartate side chain free, and the PubChem depiction of the capped molecule draws exactly that. But that record's own formula and mass, C39H67N15O16S and 1034.11 daltons, belong to the uncapped peptide, and the PubChem entry it cross-references carries an enamine in place of the Glu1-Glu2 amide carbonyl, yielding a third formula and 1073.2. A reader taking a mass from the first available record has roughly a one in three chance of taking the right one, and 1073.2 has already propagated into at least one review table.[1,6,14,32]

No molecular target has been established: no published dissociation constant, no half-maximal inhibitory concentration from a peer-reviewed assay, no stoichiometry, no competition experiment against SNAP-25 in a defined system. Over roughly two decades of commercial existence, the measurable work on this family went almost entirely to its six-residue predecessor, including the cytotoxicity screen, the skin-penetration studies and the detection of methionine oxidation in marketed products. Transferring any of those here is the inference the 2026 appraisal of this class warns against.[21,22,20,15,5]

The physical chemistry is thin in a way that matters for interpretation. A 1075 dalton peptide with five charged side chains sits well outside the envelope that cosmetic peptides have historically occupied, which one framework paper describes as under about 500 daltons and fewer than about five residues, and the ingredient-review data it summarises report minimal if any skin penetration for the shorter peptides reviewed. Measured solubility, partition and stability data for this molecule are absent from the literature read; the only stability measurement found is four days in refrigerated water in an analytical paper, and the only solubility figure is a supplier value quoted in a formulation study.[33,4,24]

There is no three-dimensional information at all, by either route. No deposited structure of the capped octapeptide exists, and a motif search over the whole structure archive finds the sequence only inside SNAP-25 constructs within SNARE complexes; PubChem holds no computed conformer for either of the substance's depictions. The helix the segment forms inside the assembled complex is a property of the protein, and whether eight capped residues populate that conformation in solution is unmeasured. For a molecule whose proposed mechanism is helix-for-helix substitution into a four-helix bundle, that is the gap closest to the centre of the question.[26,16,6,27]

Key papers on Snap-8

  1. Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry

    Ji M, Lee HS, Kim Y, Seo C, Choi S, Oh S, Min J, Park HJ, Kim JD, Jeong DH, Paik MJ (2020), Journal of Analytical Science and Technology · Validated LC-MS/MS method

    The only peer-reviewed paper devoted to this molecule: how to measure it, its charge-state behaviour, its quantification limits and the one stability figure that exists.

  2. Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, substance record UNII 8K14HJF88S

    US Food and Drug Administration, Global Substance Registration System, FDA GSRS · Regulatory substance record

    The authoritative identity record, including the acetyl and isoasparagine modifications that fix where the caps sit, and the place to see that the stated formula describes the uncapped peptide.

  3. Acetyl octapeptide-3, compound summary CID 76283482

    PubChem, PubChem, National Center for Biotechnology Information · Chemical database record

    The registry depiction consistent with the sequence and both caps, with the formula, both masses and the computed polarity descriptors.

  4. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution

    Sutton RB, Fasshauer D, Jahn R, Brunger AT (1998), Nature · X-ray crystallography

    The crystal structure of the complex the sequence comes from, which is what any competition account has to be read against.

  5. Small peptides patterned after the N-terminus domain of SNAP25 inhibit SNARE complex assembly and regulated exocytosis

    Blanes-Mira C, Merino JM, Valera E, Fernandez-Ballester G, Gutierrez LM, Viniegra S, Perez-Paya E, Ferrer-Montiel A (2004), Journal of Neurochemistry · In vitro assembly and exocytosis assays

    The nearest experimental work on N-terminal SNAP-25 peptides, and the paper that maps the essential segment to residues 22 to 44 and ties potency to helicity.

  6. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy

    Errante F, Ledwon P, Latajka R, Rovero P, Papini AM (2020), Frontiers in Chemistry · Narrative review

    Where the mechanism statement and the 43 percent figure in general circulation come from, with the manufacturer provenance visible.

  7. Peptides in Aesthetic Dermatology: Classification, Fibroblast-Centered Mechanisms, Delivery Technologies, and Clinical Evidence

    Yi KH, Kim HS, Lee HE, Choi WS, Kim JH (2026), Life · Narrative review with evidence appraisal

    A 2026 appraisal that states the limits of the evidence for this whole class, including that sequence similarity does not license treating these peptides as equivalent.

  8. Soluble N-Ethylmaleimide-Sensitive Factor Attachment Protein Receptor-Derived Peptides for Regulation of Mast Cell Degranulation

    Yang Y, Kong B, Jung Y, Park JB, Oh JM, Hwang J, Cho JY, Kweon DH (2018), Frontiers in Immunology · Cellular degranulation and SNARE assembly assays

    A worked example of the measured experiment this compound lacks, and the clearest demonstration that peptides of this class needed an added delivery sequence to reach an intracellular target.

References

  1. 1.US Food and Drug Administration, Global Substance Registration System. Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, substance record UNII 8K14HJF88S. FDA GSRS. source · database record
  2. 2.UniProt Consortium. P60880, Synaptosomal-associated protein 25, Homo sapiens. UniProtKB. source · database record
  3. 3.Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernandez-Ballester G, Ponsati B, Gutierrez L, Perez-Paya E, Ferrer-Montiel A. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science. 24:303-310. doi:10.1046/j.1467-2494.2002.00153.x · abstract only
  4. 4.Ji M, Lee HS, Kim Y, Seo C, Choi S, Oh S, Min J, Park HJ, Kim JD, Jeong DH, Paik MJ. (2020). Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry. Journal of Analytical Science and Technology. 11:34. doi:10.1186/s40543-020-00232-8 · full text read
  5. 5.Errante F, Ledwon P, Latajka R, Rovero P, Papini AM. (2020). Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Frontiers in Chemistry. 8:572923. doi:10.3389/fchem.2020.572923 · full text read
  6. 6.PubChem. Acetyl octapeptide-3, compound summary CID 76283482. PubChem, National Center for Biotechnology Information. source · database record
  7. 7.U.S. Food and Drug Administration. (2026). Drugs@FDA: FDA-Approved Drugs. Drugs@FDA database. source · database record
  8. 8.European Medicines Agency. (2026). Medicines: search for human medicines (centrally authorised medicines). European Medicines Agency medicines database. source · database record
  9. 9.Health Canada. (2026). Drug Product Database online query. Health Canada Drug Product Database. source · database record
  10. 10.U.S. Food and Drug Administration. (2026). FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated. U.S. Food and Drug Administration. source · full text read
  11. 11.World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency. source · full text read
  12. 12.US Food and Drug Administration. (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA human drug compounding. source · full text read
  13. 13.PubChem. Acetyl hexapeptide-3, compound summary CID 71587772. PubChem, National Center for Biotechnology Information. source · database record
  14. 14.PubChem. Acetyl Octapeptide-3 [INCI], compound summary CID 71587832. PubChem, National Center for Biotechnology Information. source · database record
  15. 15.Yi KH, Kim HS, Lee HE, Choi WS, Kim JH. (2026). Peptides in Aesthetic Dermatology: Classification, Fibroblast-Centered Mechanisms, Delivery Technologies, and Clinical Evidence. Life. 16:1660. doi:10.3390/life16101660 · full text read
  16. 16.Sutton RB, Fasshauer D, Jahn R, Brunger AT. (1998). Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature. 395:347-353. doi:10.1038/26412 · abstract only
  17. 17.Badilli U, Inal O. (2025). Current Approaches in Cosmeceuticals: Peptides, Biotics and Marine Biopolymers. Polymers. 17:798. doi:10.3390/polym17060798 · full text read
  18. 18.US Food and Drug Administration, Global Substance Registration System. Substance record for ACETYL HEXAPEPTIDE-8, UNII L4EL31FWIL. FDA Global Substance Registration System. source · database record
  19. 19.US Food and Drug Administration, Global Substance Registration System. Substance record for PENTAPEPTIDE-18, UNII PO4D55T1IG. FDA Global Substance Registration System. source · database record
  20. 20.Kluczyk A, Ludwiczak J, Modzel M, Kuczer M, Cebrat M, Biernat M, Bachor R. (2021). Argireline: Needle-Free Botox as Analytical Challenge. Chemistry and Biodiversity. 18:e2000992. doi:10.1002/cbdv.202000992 · abstract only
  21. 21.Grosicki M, Latacz G, Szopa A, Cukier A, Kiec-Kononowicz K. (2014). The study of cellular cytotoxicity of argireline - an anti-aging peptide. Acta Biochimica Polonica. 61:29-32. PMID 24644551 · abstract only
  22. 22.Hoppel M, Reznicek G, Kahlig H, Kotisch H, Resch GP, Valenta C. (2015). Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. European Journal of Pharmaceutical Sciences. 68:27-35. doi:10.1016/j.ejps.2014.12.006 · abstract only
  23. 23.Wongrattanakamon P, Nimmanpipug P, Sirithunyalug B, Jiranusornkul S. (2018). Molecular modeling elucidates the cellular mechanism of synaptotagmin-SNARE inhibition: a novel plausible route to anti-wrinkle activity of botox-like cosmetic active molecules. Molecular and Cellular Biochemistry. 442:97-109. doi:10.1007/s11010-017-3196-5 · abstract only
  24. 24.Shin JY, Han D, Yoon KY, Jeong DH, Park YI. (2024). Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Annals of Dermatology. 36:215-224. doi:10.5021/ad.23.136 · full text read
  25. 25.Avcil M, Akman G, Klokkers J, Jeong D, Celik A. (2020). Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. Journal of Cosmetic Dermatology. 19:328-337. doi:10.1111/jocd.13009 · abstract only
  26. 26.Sutton RB, Fasshauer D, Jahn R, Brunger AT. (1998). Neuronal synaptic fusion complex, PDB entry 1SFC. RCSB Protein Data Bank. doi:10.2210/pdb1sfc/pdb · database record
  27. 27.Blanes-Mira C, Merino JM, Valera E, Fernandez-Ballester G, Gutierrez LM, Viniegra S, Perez-Paya E, Ferrer-Montiel A. (2004). Small peptides patterned after the N-terminus domain of SNAP25 inhibit SNARE complex assembly and regulated exocytosis. Journal of Neurochemistry. 88:124-135. doi:10.1046/j.1471-4159.2003.02133.x · abstract only
  28. 28.Yang Y, Kong B, Jung Y, Park JB, Oh JM, Hwang J, Cho JY, Kweon DH. (2018). Soluble N-Ethylmaleimide-Sensitive Factor Attachment Protein Receptor-Derived Peptides for Regulation of Mast Cell Degranulation. Frontiers in Immunology. 9:725. doi:10.3389/fimmu.2018.00725 · full text read
  29. 29.Butron L, Nikolaeva-Koleva M, Sempere A, Rivero V, Fernandez-Ballester G, Espinosa A, Vergassola M, Mastrocola E, Zucchi S, Ragni L, Fernandez-Carvajal A, Mangano G, Ferrer-Montiel A, Devesa I. (2023). Design and validation of neuronal exocytosis blocking peptides as potential novel antiperspirants. Experimental Dermatology. 32:999-1006. doi:10.1111/exd.14804 · abstract only
  30. 30.Blanes-Mira C, Pastor MT, Valera E, Fernandez-Ballester G, Merino JM, Gutierrez LM, Perez-Paya E, Ferrer-Montiel A. (2003). Identification of SNARE complex modulators that inhibit exocytosis from an alpha-helix-constrained combinatorial library. Biochemical Journal. 375:159-166. doi:10.1042/BJ20030509 · abstract only
  31. 31.Ferrer-Montiel AV, Gutierrez LM, Apland JP, Canaves JM, Gil A, Viniegra S, Biser JA, Adler M, Montal M. (1998). The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking. FEBS Letters. 435:84-88. doi:10.1016/s0014-5793(98)01012-6 · abstract only
  32. 32.Pintea A, Manea A, Pintea C, Vlad RA, Birsan M, Antonoaea P, Redai EM, Ciurba A. (2025). Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review. Biomolecules. 15:88. doi:10.3390/biom15010088 · full text read
  33. 33.Bjerke DL, Li J, Gao Y, Hu P, Lintner K, Hakozaki T. (2026). A framework for the safety evaluation of peptides in cosmetics. Current Research in Toxicology. 10:100291. doi:10.1016/j.crtox.2026.100291 · full text read
  34. 34.Gutierrez LM, Viniegra S, Rueda J, Ferrer-Montiel AV, Canaves JM, Montal M. (1997). A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells. Journal of Biological Chemistry. 272:2634-2639. doi:10.1074/jbc.272.5.2634 · abstract only
  35. 35.Lee HJ, Kim D, Choi HJ, Kim S, Shin M, Kwak S, Lee DK, Kang WH. (2024). Potential role of the cell-penetrating peptide-conjugated soluble N-ethylmaleimide-sensitive factor attachment protein receptor motif of vesicle-associated membrane protein 2-patterned peptide in novel cosmeceutical skin product development. Journal of Cosmetic Dermatology. 23:666-675. doi:10.1111/jocd.15984 · abstract only

Scope. This entry describes chemistry, structure and published laboratory findings. It is not guidance on use of any kind.

Sources read: 31 distinct works. Researched 2026-11-03. Detailed review 2026-11-02. How this library is built.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.